Skip to main content
BIIB
NASDAQ Life Sciences

Canada's Drug Agency Backs Public Reimbursement for Biogen's Alzheimer's Drug LEQEMBI

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$216.65
Mkt Cap
$32.011B
52W Low
$131.52
52W High
$222.85
52W Position info
65% above low
Off High info
2.8% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BIIB sits 65% above its 52-week low of $131.52.

Summary

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of LEQEMBI for early Alzheimer's disease. This is a key regulatory milestone that clears a major hurdle for market access in Canada, where over 770,000 people live with dementia. The recommendation follows a reconsideration and moves the drug closer to provincial coverage, though negotiations through the pan-Canadian Pharmaceutical Alliance and individual provincial decisions are still pending. For Biogen, this expands the commercial opportunity for its Alzheimer's franchise, which has been a focus of recent positive developments including FDA approvals for subcutaneous dosing. The news is incremental but meaningful for a company trading near its 52-week high.

At the time of this announcement, BIIB was trading at $216.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $131.52 to $222.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $240.88 info
Change: -$11.85 (-5%) info
Market Cap: $36.058B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $240.88 info
Change: -$11.85 (-5%) info
Market Cap: $36.058B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $240.88 info
Change: -$11.85 (-5%) info
Market Cap: $36.058B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $240.88 info
Change: +$19.76 (+9%) info
Market Cap: $36.058B info
BIIB
Sep 16, 2026, 2:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $216.17
Real-time Price: $240.88 info
Change: +$24.71 (+11%) info
Market Cap: $36.058B info